Is Kadimastem Ltd (KMSTF) a Buy, Sell, or Hold?
OTC : KMSTF
Kadimastem Ltd
$3.21 USD
-$0.1 (-3.02%)
- Volume
- 29.15K
- Average Volume
- 40.24K
- Market Capitalization
- $9.5M
- P/E Ratio
- -1.55
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.07
- Year Low
- $0.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.09
Company Overview
OTC
Ronen Twito
Biotechnology
Healthcare
KMSTF
11
IL
USD
Liquidity Metrics
-0.97
0.09
0.09
0.07
0.00
Sales & Valuation
-$
0.00
-1.41
-10.46
-0.66
Profitability
-$6.33
-$26.49M
0.00%
0.00%
158.13%
-803.76%
P/E Metrics
-1.55
-0.02
-0.02
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-342.57
3/9
-$51.21M
$1.55M
$52.41M
-$9.41M
Key Metrics (TTM)
$54.83M
0.00
-2.21
0.09
158.13%
678.62%
-64.46%
-9.57%
-496 days
Company Executives
| Name | Title |
|---|---|
| Ronen Twito | Chief Executive Officer & Executive Chairman |
| Yossi Ben-Yossef | Honorary President & Strategic Consultant |
| Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director |
| Olivier Samuel | Vice President of Research and Development & Director |
| Uri Ben-Or | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Kadimastem Ltd (OTC:KMSTF) Stock
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes. Founded in 2008, Kadimastem maintains its headquarters in Ness Ziona, Israel. ...
Frequently Asked Questions
-
What is the current Kadimastem Ltd (KMSTF) stock price?
-
Kadimastem Ltd(OTC:KMSTF) stock price is $3.21 in the last trading session. During the trading session, KMSTF stock reached the peak price of $9.07082 while $0.6404 was the lowest point it dropped to. The percentage change in KMSTF stock occurred in the recent session was --3.02% while the dollar amount for the price change in KMSTF stock was -$0.1.
-
KMSTF's industry and sector of operation?
-
The OTC listed KMSTF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KMSTF?
-
Ronen Twito | Chief Executive Officer & Executive Chairman
Yossi Ben-Yossef | Honorary President & Strategic Consultant
Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director
Olivier Samuel | Vice President of Research and Development & Director
Uri Ben-Or | Chief Financial Officer -
How many employees does KMSTF have?
-
Number of KMSTF employees currently stands at 11. KMSTF operates from Pinchas Sapir 7, Ness Ziona, None 74140, IL.
-
Link for KMSTF official website?
-
Official Website of KMSTF is: https://www.kadimastem.com
-
How do I contact KMSTF?
-
KMSTF could be contacted at phone #972 73 797 1600 and can also be accessed through its website. KMSTF operates from Pinchas Sapir 7, Ness Ziona, None 74140, IL.
-
How many shares of KMSTF are traded daily?
-
The average number of KMSTF shares traded daily for last 3 months was 40.24K.
-
What is the market cap of KMSTF currently?
-
The market value of KMSTF currently stands at $9.5M with its latest stock price at $3.21